A novel function for platelet-derived growth factor D: Induction of osteoclastic differentiation for intraosseous tumor growth

Oncogene

Volumn 31, Issue 42, 2012, Pages 4527-4535

  Huang, W ^a   Fridman, Y ^a,b   Bonfil, R D ^a   Ustach, C V ^a   Conley Lacomb, M K ^a   Wiesner, C ^a,c   Saliganan, A ^a   Cher, M L ^a   Kim, H R C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

bone responses; osteoclastic differentiation; PDGF D; prostate cancer

Indexed keywords

NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR D; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL CELL; ARTICLE; BONE METASTASIS; BONE TUMOR; CELL ACTIVATION; CELL DIFFERENTIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION;

ACID PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LYMPHOKINES; MALE; MICE; MICE, SCID; MUTATION; NIH 3T3 CELLS; OSTEOCLASTS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-SIS; RANK LIGAND; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIBIA;

MUS;

EID: 84867748654     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.573     Document Type: Article

References (37)

1. Buijs JT, van der Pluijm G (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett 73: 177-193.
2. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2: 276-312.
3. Reigstad LJ, Varhaug JE, Lillehaug JR (2005) Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272: 5723-5741.
4. Fredriksson L, Li H, Fieber C, Li X, Eriksson U (2004) Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23: 3793-3802.
5. Ustach CV, Kim H-RC (2005) Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25: 6279-6288.
6. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J et al. (2010) A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70: 9631-9640.
7. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M et al. (1999) Tyrosine kinases expressed in Vivo by human prostate cancer bone marrow metastases and loss of the Type 1 insulin-like growth factor receptor. Am J Pathol 155: 1271-1279.
8. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
9. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM et al. (2007) Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13: 5816-5824.
10. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD (2004) Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 10(12 Pt 1): 4192-4197.
11. van der Poel HG (2004) Smart drugs in prostate cancer. Eur Urol 45: 1-17.
12. Ustach CV, Taube ME, Hurst Jr NJ, Bhagat S, Bonfil RD, Cher ML et al. (2004) A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 64: 1722-1729.
13. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180: 1154-1160.
14. Kubota K, Wakabayashi K, Matsuoka T (2003) Proteome analysis of secreted proteins during osteoclast differentiation using two different methods: two-dimensional electrophoresis and isotope-coded affinity tags analysis with two-dimensional chromatography. Proteomics 3: 616-626.
15. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055.
16. Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3: 41-49.
17. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA et al. (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3: 517-521.
18. Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24: 790-799.
19. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
20. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25.
21. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244.
22. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
23. Taichman RS, Loberg RD, Mehra R, Pienta KJ (2007) The evolving biology and treatment of prostate cancer. J Clin Invest 117: 2351-2361.
24. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354: 2006-2013.
25. Breccia M, Alimena G (2009) The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leuk Res 33: 871-875.
26. Chaudhary LR, Hofmeister AM, Hruska KA (2004) Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 34: 402-411.
27. Godwin SL, Soltoff SP (1997) Extracellular calcium and platelet-derived growth factor promote receptor-mediated chemotaxis in osteoblasts through different signaling pathways. J Biol Chem 272: 11307-11312.
28. Mehrotra M, Krane SM, Walters K, Pilbeam C (2004) Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem 93: 741-752.
29. Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K (2002) Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 17: 257-265.
30. Himeno M, Enomoto H, Liu W, Ishizeki K, Nomura S, Kitamura Y et al. (2002) Impaired vascular invasion of Cbfa1-deficient cartilage engrafted in the spleen. J Bone Miner Res 17: 1297-1305.
31. Robbins JR, McGuire PG, Wehrle-Haller B, Rogers SL (1999) Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. Dev Biol 212: 255-263.
32. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T et al. (2004) PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 104: 3198-3204.
33. Deininger MW, Druker BJ (2003) Specific targeted therapy of chronic myelogen-ous leukemia with imatinib. Pharmacol Rev 55: 401-423.
34. Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9: 271-281.
35. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
36. Ehnman M, Li H, Fredriksson L, Pietras K, Eriksson U (2009) The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth. Oncogene 28: 534-544.
37. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S et al. (2007) Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170: 2100-2111.